Compare stocks

Argenx SE is a biotechnology company primarily engaged in the development of antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The company leverages its proprietary SIMPLE Antibody™ platform to create differentiated immunology solutions. One of its flagship products is efgartigimod, designed to target the neonatal Fc receptor (FcRn) to modulate antibody levels, which has gained significant attention in therapeutic areas such as neuromuscular disorders. Founded in 2008, Argenx is headquartered in Ghent, Belgium, and has expanded its operations globally. The company's strategic positioning lies in its ability to combine deep insights into disease biology with cutting-edge technology to create novel treatments. Sources: - Argenx Official Website: www.argenx.com - "Argenx - Company Profile and News," Bloomberg, www.bloomberg.com

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.